Paramyxoviridae (e.g., Parainfluenza Virus, Respiratory Syncytial Virus, Rinderpest Virus, Sendai Virus, Canine Tracheobronchitis Virus, Turkey Rhinotracheitis Virus, Etc.) Patents (Class 424/211.1)
  • Patent number: 10654898
    Abstract: Recombinant paramyxoviruses including a viral genome encoding a heterologous gene are provided. In several embodiments, the recombinant paramyxovirus is a recombinant parainfluenza virus, such as a recombinant PIV3 including a viral genome encoding a heterologous respiratory syncytial virus F ectodomain linked to the transmembrane domain and the cytoplasmic tail of the F protein from the PIV3. Nucleic acid molecules including the genome of a recombinant paramyxoviruses are also provided. The recombinant viruses may advantageously be used in vaccine formulations, such as for vaccines against parainfluenza virus and respiratory syncytial virus.
    Type: Grant
    Filed: January 20, 2016
    Date of Patent: May 19, 2020
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Serices
    Inventors: Peter Collins, Bo Liang, Shirin Munir, Anne Schaap Nutt, Ursula Buchholz, Natalie Mackow, Peter Kwong, Barney Graham, Jason McLellan
  • Patent number: 10596234
    Abstract: This disclosure provides vaccine and therapeutic active against viral infections such as herpes simplex virus 1 (HSV-1) infections.
    Type: Grant
    Filed: October 30, 2017
    Date of Patent: March 24, 2020
    Assignee: University of Southern California
    Inventors: Pinghui Feng, Jun Zhao
  • Patent number: 10377798
    Abstract: Compositions and methods useful for producing an immune response in a subject specific for the RSV G protein are described herein. The new methods and compositions described herein are made possible by the development of a new recombinant RSV G protein fragment, which has been engineered for in vitro production and is antigenically similar to the native RSV G protein. The recombinant RSV G protein fragment is capable of inducing the production of RSV G-specific antibodies when injected into a subject. These antibodies can recognize both RSV A and RSV B strains and inhibit infection of both viruses. Accordingly, the compositions and methods described herein may be useful in protecting subjects from RSV infection via immunization, raising antibodies specific for RSV, which can in turn be used to treat RSV infection.
    Type: Grant
    Filed: December 2, 2014
    Date of Patent: August 13, 2019
    Assignee: The United States of America, as rerpresented by the Secretary, Department of Health and Human Services
    Inventors: Surender Khurana, Hana Golding
  • Patent number: 10058603
    Abstract: The disclosure provides immunogenic compositions comprising human picornavirus peptides derived from structural proteins of the virus, constructs comprising the peptides, the peptides themselves and their use in the prevention of picornavirus infection and disease. Particular peptides from VP4 and VP1 are disclosed.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: August 28, 2018
    Assignee: GlaxoSmithKline Biologicals S.A.
    Inventors: Guy Baudoux, Mathieu Boxus, Brigitte Colau, Martine Marchand
  • Patent number: 10017543
    Abstract: Disclosed are Respiratory Syncytial Virus (RSV) antigens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the antigens and methods of producing the antigens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the antigen to the subject.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: July 10, 2018
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter D. Kwong, Barney S. Graham, Jason S. McLellan, Jeffrey Boyington, Lei Chen, Man Chen, Gwo-Yu Chuang, Ivelin Stefanov Georgiev, Jason Gorman, Michael Gordon Joyce, Masaru Kanekiyo, Gilad Ofek, Marie Pancera, Mallika Sastry, Cinque Soto, Sanjay Srivatsan, Guillaume Stewart-Jones, Yongping Yang, Baoshan Zhang, Tongqing Zhou
  • Patent number: 9974850
    Abstract: Immunogenic compositions comprising viral vectors and surfactants are provided. Methods for administration and preparation of such compositions are also provided.
    Type: Grant
    Filed: March 25, 2016
    Date of Patent: May 22, 2018
    Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM
    Inventors: Maria A. Croyle, Stephen Clay Schafer
  • Patent number: 9957486
    Abstract: Described herein are RSV polynucleotide sequences that make use of multiple codons that are containing silent nucleotide substitutions engineered in multiple locations in the genome, wherein the substitutions introduce a numerous synonymous codons into the genome. Due to the large number of defects involved, the attenuated viruses disclosed herein provide a means of producing attenuated, live vaccines against RSV.
    Type: Grant
    Filed: February 7, 2014
    Date of Patent: May 1, 2018
    Assignees: The United States of America, as represented by the Secretary, Dept. of Health and Human Services, The Research Foundation For the State University of New York
    Inventors: Peter L. Collins, Cyril Le Nouën, Linda G. Brock, Ursula J. Buchholz, Joshua Marc DiNapoli, Steffen Mueller, Eckard Wimmer
  • Patent number: 9951349
    Abstract: Compositions for transient but prolonged exogenous mRNA expression through the use of the transcription system of negative strand RNA viruses, and methods of use thereof are disclosed. In some embodiments, the system contains only RNAs and does not include any DNA molecules. The compositions typically include an RNA template unit (rTeUn) that includes a virus regulatory sequences operably linked to a coding sequence of interest. The rTeUn is typically transfected to a host cell's cytoplasm in the presence of virus expression system proteins that mediate replication of the rTeUn and transcription of the transgene. The rTeUn RNA bonded to viral proteins exhibits high resistance to degradation, prolonged duration of expression, and is free of viral genes. The compositions can be used to reprogram cell. For example, the compositions and methods can be used to redirected lymphocytes to target cancer cells, or to dedifferentiate somatic cells into induce pluripotent stem cells.
    Type: Grant
    Filed: September 27, 2012
    Date of Patent: April 24, 2018
    Assignee: Yale University
    Inventors: Peter M. Rabinovich, Sherman M. Weissman
  • Patent number: 9738689
    Abstract: Disclosed are immunogens including a recombinant RSV F protein stabilized in a prefusion conformation. Also disclosed are nucleic acids encoding the immunogens and methods of producing the immunogens. Methods for generating an immune response in a subject are also disclosed. In some embodiments, the method is a method for treating or preventing a RSV infection in a subject by administering a therapeutically effective amount of the immunogen to the subject.
    Type: Grant
    Filed: March 12, 2014
    Date of Patent: August 22, 2017
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Peter Kwong, Barney Graham, Jason McLellan, Man Chen, Michael Gordon Joyce, Baoshan Zhang, Tongqing Zhou
  • Patent number: 9718873
    Abstract: The invention features a novel influenza antibody that specifically binds to influenza hemagglutinin and reduces or inhibits hemagglutinin binding to sialic acid. The invention also provides methods, compositions, and kits featuring the novel antibody and its use in preventing or treating influenza infection.
    Type: Grant
    Filed: February 3, 2014
    Date of Patent: August 1, 2017
    Assignees: Duke University, Children's Medical Center Corporation
    Inventors: James Whittle, Stephen C. Harrison, Barton F. Haynes, Hua-Xin Liao, M. A. Moody, Thomas B. Kepler, Aaron G. Schmidt
  • Patent number: 9624475
    Abstract: Provided herein are recombinant respiratory syncytial viruses that contain mutations that make the disclosed viruses attractive vaccine candidates. The viruses disclosed contain attenuating mutations designed to have increased genetic and phenotypic stability. Desired combinations of these mutations can be made to achieve desired levels of attenation. Exemplary vaccine candidates are described. Also provided are polynucleotides capable of encoding the described viruses, as wells as methods for producing the viruses and methods of use.
    Type: Grant
    Filed: March 13, 2013
    Date of Patent: April 18, 2017
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter L. Collins, Cindy L. Luongo, Ursula J. Buchholz, Brian R. Murphy
  • Patent number: 9585953
    Abstract: The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumor origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient.
    Type: Grant
    Filed: March 22, 2012
    Date of Patent: March 7, 2017
    Assignee: MUCOSIS B.V.
    Inventors: Cornelis Johannes Leenhouts, Bert Jan Haijema, Maarten Leonardus van Roosmalen, Petrus Josephus Marie Rottier, Cornelis Alexander Maria de Haan, Berend Jan Bosch
  • Patent number: 9561271
    Abstract: The present application relates to the field of immunology, in particular, a vaccine composition of respiratory syncytial virus (RSV) surface proteins, Fusion (F) and Glycoprotein (G) proteins subunit vaccine preferentially mixed with the immune cell targeting and enhancer, nanoemulsion to induce a protective immune response and avoid vaccine-induce disease enhancement.
    Type: Grant
    Filed: September 10, 2012
    Date of Patent: February 7, 2017
    Assignee: NanoBio Corporation
    Inventors: Ali I. Fattom, Tarek Hamouda, Vira Bitko, James R. Baker, Jr.
  • Patent number: 9533036
    Abstract: Provided are methods of generating an immune response to any of various antigens including foreign antigens such as infectious agent antigens. In general, the method comprises administering an expression vector encoding a transcription unit encoding a secretable fusion protein, the fusion protein containing the foreign antigen and CD40 ligand and also administering the encoded fusion protein. In another approach, an immune response to the foreign antigen is elicited using the encoded fusion protein without administering the vector. The invention methods may be used to immunize an individual against an infectious agent such as influenza virus. Methods of obtaining an immune response in older individuals also is described.
    Type: Grant
    Filed: November 6, 2006
    Date of Patent: January 3, 2017
    Assignee: MicroVAX, LLC
    Inventors: Yucheng Tang, Albert Deisseroth
  • Patent number: 9408908
    Abstract: Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositions include host defense peptides, polyphosphazenes and immunostimulatory sequences to enhance the immune response to a coadministered antigen.
    Type: Grant
    Filed: February 15, 2013
    Date of Patent: August 9, 2016
    Inventors: Sylvia van den Hurk, Volker Gerdts, Andrew Potter, Lorne Babiuk, Robert Hancock, Scott Halperin, Jennifer Kovacs-Nolan, George Mutwiri, Song Lee, Mi-Na Kweon, Jason Kindrachuk, Melissa Elliott
  • Patent number: 9254265
    Abstract: Nucleic acid immunization is achieved by delivering RNA encapsulated within a liposome. The RNA encodes an immunogen of interest, and the liposome has a diameter in the range of 60-180 nm, and ideally in the range 80-160 nm. Thus the invention provides a liposome having a lipid bilayer encapsulating an aqueous core, wherein: (i) the lipid bilayer has a diameter in the range of 60-180 nm; and (ii) the aqueous core includes a RNA which encodes an immunogen. These liposomes are suitable for in vivo delivery of the RNA to a vertebrate cell and so they are useful as components in pharmaceutical compositions for immunizing subjects against various diseases.
    Type: Grant
    Filed: August 31, 2011
    Date of Patent: February 9, 2016
    Assignee: NOVARTIS AG
    Inventors: Andrew Geall, Ayush Verma
  • Publication number: 20150140102
    Abstract: The present invention pertains to a method for producing a medicinal product comprising a biologically active protein comprising the steps of providing an aqueous composition comprising a solvent, the biologically active protein and between 20% w/w and 60% w/w of a non-polymeric sugar, freezing the composition, thereby forming at least one frozen body comprising the solvent in frozen form, putting the frozen body in a drying apparatus while being carried by a support, the support comprising one or more restraining elements that define one or more boundaries of the support, wherein at most 30% of the surface of the body is contiguous with the one or more restraining elements, reducing the pressure in the drying apparatus below atmospheric pressure, providing heat to the body in order to sublimate the frozen solvent of the body and obtain a dried body. The invention also pertains to a product obtainable by this method.
    Type: Application
    Filed: July 9, 2013
    Publication date: May 21, 2015
    Inventors: Kevin O'Connell, Sandhya Buchanan
  • Patent number: 9034343
    Abstract: The invention provides self replicating infectious recombinant paramyxoviruses. The recombinant paramyxovirus preferably have one or more attenuating mutations. In some embodiments, the recombinant paramyxovirus has a separate variant polynucleotide encoding a P protein and a separate monocistronic polynucleotide encoding a V protein. In some embodiments, recombinant paramyxovirus have at least one temperature sensitive mutation and one non-temperature sensitive mutation. Also provided are compositions and methods for using the recombinant paramyxoviruses as described herein.
    Type: Grant
    Filed: January 10, 2006
    Date of Patent: May 19, 2015
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Mario H. Skiadopoulos, Brian R. Murphy, Peter L. Collins, Sheila Nolan
  • Patent number: 9011876
    Abstract: The present invention features live, attenuated respiratory syncytial viruses (RSV) useful as vaccines against RSV infection and/or the development of severe RSV-associated illnesses. The disclosed viruses are attenuated to the extent of being nonpathogenic when administered to a subject but substantially retain the antigenic and immunogenic properties of wild-type RSV.
    Type: Grant
    Filed: November 3, 2009
    Date of Patent: April 21, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Mary K. Yagodich, Michael P. Citron, Daniel J. Distefano, Daniel L. Krah, Xiaoping Liang
  • Patent number: 8999637
    Abstract: The invention relates to vectors comprising two or more homologous nucleotide sequences and methods for generating them. The invention concerns substituting bases in the homologous nucleotide sequences with different bases that do not alter the encoded amino acid sequence. The invention allows for the reduction of intramolecular recombination between homologous nucleotide sequences, in particular in mammalian cells. The invention further relates to nucleotide sequences containing substituted bases.
    Type: Grant
    Filed: November 20, 2009
    Date of Patent: April 7, 2015
    Assignee: Bavarian Nordic A/S
    Inventor: Robin Steigerwald
  • Patent number: 8993624
    Abstract: The present invention relates to the use of a therapeutically effective amount of abscisic acid (ABA) or its analogs to treat or prevent inflammation induced by exposure to lipopolysaccharide (LPS) or respiratory inflammation. The invention also relates to methods and composition for enhancing vaccine efficacy using ABA.
    Type: Grant
    Filed: May 26, 2011
    Date of Patent: March 31, 2015
    Assignee: Virginia Tech Intellectual Properties, Inc.
    Inventors: Josep Bassaganya-Riera, Amir Guri, Raquel Hontecillas
  • Patent number: 8974797
    Abstract: The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines.
    Type: Grant
    Filed: January 30, 2009
    Date of Patent: March 10, 2015
    Assignee: University of Massachusetts
    Inventor: Trudy Morrison
  • Publication number: 20150056246
    Abstract: The present invention relates to a probiotic cell transformed with a construct suitable to overexpress and display on the surface of the probiotic cell a fusion protein comprising at least a portion of a transport protein coupled to at least a portion of one or more antigenic proteins or peptides. Probiotic-derived vesicles displaying this fusion protein as well as methods of inducing an immune response using the probiotic cells or vesicles are also disclosed.
    Type: Application
    Filed: March 13, 2013
    Publication date: February 26, 2015
    Inventors: David A. Putnam, Joseph Rosenthal, Chung-Jr Huang, Matthew Delisa, Susana Mendez
  • Publication number: 20150050305
    Abstract: Immunogenic compositions directed against Hendra and/or Nipah viruses, and methods of its use, are provided. In addition, methods of distinguishing subjects vaccinated with the immunogenic compositions of the invention from those infected with Hendra and/or Nipah virus are provided.
    Type: Application
    Filed: May 14, 2012
    Publication date: February 19, 2015
    Applicant: ZOETIS LLC
    Inventors: Martin Elhay, Christopher C. Broder, Jin-an Huang
  • Publication number: 20150050307
    Abstract: Materials and methods useful for generating highly mannosylated pseudotyped lentiviral vector particles comprising a Vpx protein are provided.
    Type: Application
    Filed: March 29, 2013
    Publication date: February 19, 2015
    Inventors: Christopher James Nicolai, Semih U. Tareen
  • Publication number: 20150017207
    Abstract: Compositions and methods are provided that enable activation of innate immune responses through RIG-I like receptor signaling. The compositions and methods incorporate synthetic nucleic acid pathogen associated molecular patterns (PAMPs) that comprise elements initially characterized in, and derived from, the hepatitis C virus genome.
    Type: Application
    Filed: July 9, 2014
    Publication date: January 15, 2015
    Applicant: University of Washington through its Center for Commercialization
    Inventors: Michael J. Gale, JR., Gretja Schnell, Yueh-Ming Loo
  • Patent number: 8926988
    Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: January 6, 2015
    Assignees: Centre National de la Recherche Scientifique, Universite Claude Bernard de Lyon 1, Les Hospices Civils de Lyon
    Inventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
  • Patent number: 8920812
    Abstract: The present invention relates to chimeric RSV-F polypeptide and lentivirus or alpha-retrovirus GAG-based virus-like particles (VLPs). The present invention also includes methods of making and using such chimeric VLPs. In certain embodiments, the GAG polypeptide of the chimeric VLPs comprises an HIV or ALV GAG polypeptide.
    Type: Grant
    Filed: November 3, 2010
    Date of Patent: December 30, 2014
    Assignee: Takeda Vaccines, Inc.
    Inventor: Joel R. Haynes
  • Patent number: 8906386
    Abstract: The present application concerns mutant proteins of the fusion protein (F protein) of the parainfluenza virus (PIV) which are currently indexed as type 5 PIV (PIV-5 or PIV5) and type 2 PIV (PIV-2 or PIV2). The present application concerns products deriving therefrom, such as: nucleic acids, vectors, cells, fusion inhibitors of the antibody, aptamer, interfering RNA type; myelomas, hybridomas; stem and progenitor cells. The present application also concerns mutant proteins and products derived therefrom for use in medical and biotechnological applications.
    Type: Grant
    Filed: November 17, 2009
    Date of Patent: December 9, 2014
    Assignees: Centre National de la Recherche Scientifique, Universite Claude Bernard de Lyon 1, Les Hospices Civils de Lyon
    Inventors: Manuel Melchior Jean-Pierre Rosa Calatrava, Olivier Terrier, Francois Edouard Julien Durupt
  • Patent number: 8900623
    Abstract: The present invention is directed to a composition, kit and method for delivering a soft flowable gel to a flock of poultry in barns, but can also be used in hatcheries or free range farms, for treating poultry with a therapeutic agent. The soft flowable gel comprises water, a gelling agent, a therapeutic agent and between about 0.05% and 0.15% xanthan gum.
    Type: Grant
    Filed: July 27, 2010
    Date of Patent: December 2, 2014
    Assignee: Vetech Laboratories Inc.
    Inventor: Eng-Hong Lee
  • Publication number: 20140341950
    Abstract: The present invention encompasses engineered APMV compositions or vaccines. The vaccine or composition may be a recombinant APMV composition or vaccine. The present invention encompasses methods for modifying the genome of APMV to produce recombinant APMV; modified APMV prepared by such methods; DNA and protein sequences; and methods for infecting cells and host animals with such recombinant APMV.
    Type: Application
    Filed: May 15, 2013
    Publication date: November 20, 2014
    Applicants: UNIVERSITY OF GEORGIA RESEARCH FOUNDATION, INC., MERIAL LIMITED
    Inventors: Michel Bublot, Teshome Mebatsion, Joyce Pritchard, Egbert Mundt
  • Patent number: 8889146
    Abstract: The present disclosure provides immunogenic compositions that include at least two paramyxovirus F protein antigens selected from human metapnuemovirus (hMPV), paarainfluenza virus (PIV) and respiratory syncytial virus (RSV). The antigens of the disclosed compositions are recombinant F protein polypeptides, which have been modified to stabilize the trimeric prefusion conformation. Nucleic acids encoding the antigens, as well as methods for their production and use are also provided.
    Type: Grant
    Filed: June 24, 2010
    Date of Patent: November 18, 2014
    Assignee: GlaxoSmithKline Biologicals, SA
    Inventors: Ventzislav B. Vassilev, Virginie Van Scherpenzeel Thim, Normand Blais, Patrick Rheault
  • Publication number: 20140335049
    Abstract: Fraction A of Quil A can be used together with at least one other adjuvant for the preparation of an adjuvant composition, where the included adjuvant components act synergistically to enhance level of immune response and have synergistic immunomodulating activity on the co-administered antigens or immunogens. Other adjuvants can comprise saponins, naturally occurring, synthetic or semisynthetic saponin molecules; e.g. saponins and saponin fractions from Quil A, cell wall skeleton, block polymers, TDM, lipopeptides, LPS and LPS-derivatives, Lipid A from different bacterial species and derivatives thereof, e.g., monophosphoryl lipid A, CpG variants, CT and LT or fractions thereof.
    Type: Application
    Filed: July 29, 2014
    Publication date: November 13, 2014
    Inventors: Bror Morein, Karin Lövgren Bengtsson, Jill Ekström, Katarina Ranlund, Kefei Hu
  • Publication number: 20140314809
    Abstract: The invention provides a method of identifying an antigen from a pathogen or a disease antigen comprising the use of an adenoviral vector array comprising two or more different adenoviral vectors, wherein each adenoviral vector comprises a nucleic acid sequence encoding a different antigen of a pathogen. The adenoviral vectors are administered to antigen presenting cells (APCs) in vitro or to an animal in vivo. The immunogenicity of the antigen is measured by screening for an immune response from effector T lymphocytes in vitro and by screening for the absence of pathogen-induced disease onset in vivo.
    Type: Application
    Filed: April 19, 2013
    Publication date: October 23, 2014
    Inventors: Joseph T. Bruder, Imre Kovesdi, Duncan L. McVey, Douglas E. Brough, C. Richter King, Denise Louise Doolan, Joao Carlos Aguair, Daniel John Carucci, Martha Sedegah, Walter R. Weiss, Keith Limbach
  • Patent number: 8858938
    Abstract: The present invention relates to monoclonal antibodies that bind or neutralize Hendra or Nipah virus. The invention provides such antibodies, fragments of such antibodies retaining Hendra or Nipah virus-binding ability, fully human antibodies retaining Hendra or Nipah virus-binding ability, and pharmaceutical compositions including such antibodies. The invention further provides for isolated nucleic acids encoding the antibodies of the invention and host cells transformed therewith. Additionally, the invention provides for prophylactic, therapeutic, and diagnostic methods employing the antibodies and nucleic acids of the invention.
    Type: Grant
    Filed: September 13, 2013
    Date of Patent: October 14, 2014
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Henry M. Jackson Foundation of the Advancement of Military Medicine, Inc.
    Inventors: Dimiter S. Dimitrov, Zhongyu Zhu, Christopher C. Broder
  • Patent number: 8852608
    Abstract: The present invention relates to novel respiratory syncytial virus (RSV) F peptides and compositions comprising them. The present invention also relates to methods of evaluating anti-RSV antibody binding to F peptides. The present invention also relates to antibodies that immunospecifically bind to an F peptide of the present invention. The invention further provides methods and protocols for the administration of F peptides and/or antibodies that immunospecifically bind to F peptides for the prevention, neutralization, treatment of RSV infection. Additionally, the methods of the invention may be useful for the treatment, prevention and the amelioration of symptoms associated with RSV infection.
    Type: Grant
    Filed: December 23, 2009
    Date of Patent: October 7, 2014
    Assignee: MedImmune, LLC
    Inventors: Josephine McAuliffe, Frances Palmer-Hill, Qing Zhu, Joann Suzich
  • Patent number: 8846051
    Abstract: Methods of producing a pathogen with reduced replicative fitness are disclosed, as are attenuated pathogens produced using the methods. In particular examples, the method includes deoptimizing one or more codons in a coding sequence, thereby reducing the replicative fitness of the pathogen. Methods of using the attenuated pathogens as immunogenic compositions are also disclosed.
    Type: Grant
    Filed: October 7, 2005
    Date of Patent: September 30, 2014
    Assignee: The United States of America as represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention
    Inventors: Olen M. Kew, Cara C. Burns, Jing Shaw, Raymond Campagnoli, Jacqueline Quay
  • Patent number: 8846056
    Abstract: Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogues thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogues thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogues thereof.
    Type: Grant
    Filed: August 4, 2010
    Date of Patent: September 30, 2014
    Assignee: The United States of America as Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control
    Inventors: Larry J. Anderson, Lia M. Haynes, Ralph A. Tripp
  • Publication number: 20140271710
    Abstract: The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, in sucrose, arginine, and methionine. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Inventors: Sandhya BUCHANAN, Kevin O'CONNELL
  • Publication number: 20140271711
    Abstract: The invention provides an adenovirus or adenoviral vector characterized by comprising a nucleic acid sequence encoding one or more Respiratory Syncytial Virus (RSV) antigens and one or more particular nucleic acid sequences or one or more particular amino acid sequences, or portions thereof, pertaining to, for example, an adenoviral pIX protein, DNA polymerase protein, penton protein, hexon protein, and/or fiber protein, as well as a method of inducing an immune response against RSV in a mammal by administering the adenovirus or adenoviral vector to the mammal.
    Type: Application
    Filed: October 5, 2012
    Publication date: September 18, 2014
    Inventors: Douglas E. Brough, Jason G.D. Gall, Duncan McVey
  • Publication number: 20140271709
    Abstract: The present invention discloses liquid stable bovine vaccines that comprise a live attenuated virus, and a sugar alcohol. The present invention also discloses the manufacture of such vaccines and methods of protecting an animal by administration of such vaccines.
    Type: Application
    Filed: March 10, 2014
    Publication date: September 18, 2014
    Inventors: Brad Eddy, Zhisong QIAO, Kevin O'Connell
  • Publication number: 20140248314
    Abstract: The invention relates to pre-fusion RSV F protein and polypeptides that contain one or more amino acid mutations that stabilize the pre-fusion conformation or destabilize the post-fusion conformation. The invention also relates to methods for inducing an immune response to pre-fusion RSV F.
    Type: Application
    Filed: May 14, 2012
    Publication date: September 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Kurt Swanson, Andrea Carfi
  • Publication number: 20140248313
    Abstract: Methods and compositions for enhancing an immune response to a selected antigen are described. The methods are useful for the treatment and prevention of microbial infections, such as infections caused by bacteria, viruses, fungi and parasites. The methods and compositions include host defense peptides, polyphosphazenes and immunostimulatory sequences to enhance the immune response to a coadministered antigen.
    Type: Application
    Filed: February 15, 2013
    Publication date: September 4, 2014
    Applicants: University of Saskatchewan, International Vaccine Institute, Dalhousie University, The University of British Columbia
    Inventors: University of Saskatchewan, The University of British Columbia, Dalhousie University, International Vaccine Institute
  • Patent number: 8778354
    Abstract: Compositions and methods are provided for the treatment or prevention of RSV disease by modulating RSV infection and immunity. In particular, amino acid sequences in the RSV G glycoprotein, containing the chemokine motif defined as C-X-X-X-C (or CX3C), are identified that are essential in causing RSV infection and disease. The chemokine motif is biologically active and participates in virus binding to and infection of susceptible cells. The prevention or treatment of RSV infection is achieved by interfering with the motif, such as by administering a vaccine in which the motif is altered or by administration or induction of blocking molecules that inhibit the biological activity of the motif.
    Type: Grant
    Filed: January 25, 2012
    Date of Patent: July 15, 2014
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ralph A. Tripp, Les Jones, Larry J. Anderson
  • Patent number: 8771706
    Abstract: Immunogenic polypeptides corresponding to one or more RSV G glycoproteins, or analogs thereof, are provided as components of vaccines. The inventive compositions are useful as both a prophylactic and therapeutic for the prevention and treatment of RSV infections and associated pulmonary or other diseases. The inventive immunogens include regions of the RSV G protein, specifically, amino acid residues 164-176 of RSV G A2 protein or analogs thereof. This inventive immunogen is operable alone or in combination with other polypeptides such as the RSV G protein amino acid residues 155-206, or other vaccines such as live RSV vaccines, or inactivated RSV vaccines or immunogenic analogs thereof.
    Type: Grant
    Filed: February 11, 2013
    Date of Patent: July 8, 2014
    Assignee: The United States of America, as represented by the Secretary of the Department of Health and Human Services
    Inventors: Larry J. Anderson, Lia M. Haynes, Ralph A. Tripp
  • Publication number: 20140186397
    Abstract: The present invention relates to a Sendai virus or recombinant Sendai virus vector. In particular the present invention provides methods, vectors, formulations, compositions, and kits for a modified Enders strain Sendai viral vector. An immunogenic vector can be used in any in vitro or in vivo system. Moreover, some embodiments include vectors for imaging virus growth, location and transmission.
    Type: Application
    Filed: April 13, 2012
    Publication date: July 3, 2014
    Inventors: Julia Lea Hurwitz, Toru Takimoto, Charles John Russell, Allen Portner, Karen Slobod
  • Publication number: 20140170185
    Abstract: The present invention pertains to an emulsion comprising an aqueous phase and an oily phase, the aqueous phase containing a non-live medicinal substance, wherein the aqueous phase comprises at least 30% w/w sugar. The invention also pertains to a method to shield a medicinal substance present in an aqueous phase emulsified with an oily phase, from interaction with the oily phase, and to a vaccine comprising as an antigen a killed micro-organism or a subunit of a micro-organism, the antigen being present in an aqueous phase that is dispersed in an oily phase, wherein the aqueous phase comprises at least 30% w/w sugar.
    Type: Application
    Filed: December 11, 2013
    Publication date: June 19, 2014
    Inventors: Erwin MOMBARG, Theodorus JANSEN, Henricus Johannes Maria JAGT
  • Publication number: 20140141042
    Abstract: The invention relates to an expression system comprising polynucleotides encoding proteins, wherein the expression system comprises a first polynucleotide encoding at least one protein, peptide or variant thereof, which induces a T cell response, and a second polynucleotide encoding at least one protein peptide or variant thereof, which induces an anti-pathogenic B cell response. The invention further relates to protein mixtures encoded by the expression system and cells comprising the expression system or the protein mixture and pharmaceutical compositions comprising the expression system or the protein mixture. The expression system, polynucleotides, proteins, cells, and pharmaceutical compositions are useful in the prophylaxis or treatment of infections. The invention further relates to nucleotide constructs which comprises, essentially consists or consists of a polynucleotide encoding a modified influenza hemagglutinin (HA).
    Type: Application
    Filed: December 30, 2011
    Publication date: May 22, 2014
    Applicant: OKAIROS AG
    Inventors: Alessandra Vitelli, Alfredo Nicosia, Riccardo Cortese
  • Publication number: 20140141043
    Abstract: Disclosed are compositions, vectors, kits, and methods for inducing an immune response against avian infectious bronchitis virus (IBV). In particular, the compositions, vectors, kits, and methods may be utilized to immunize poultry against disease associated with IBV infection or to protect poultry from IBV infection altogether.
    Type: Application
    Filed: March 15, 2013
    Publication date: May 22, 2014
    Applicant: AUBURN UNIVERSITY
    Inventors: Haroldo Enrique Toro Guzman, Qingzhong Yu
  • Publication number: 20140141041
    Abstract: The present invention shows that intranasal administration of E1/E3-defective adenovirus particles may confer rapid and broad protection against viral and bacterial pathogens in a variety of disease settings. Protective responses lasted for many weeks in a single-dose regimen in animal models. When a pathogen-derived antigen gene was inserted into the E1/E3-defective adenovirus genome, the antigen-induced protective immunity against the specific pathogen was elicited before the adenovirus-mediated protective response declined away, thus conferring rapid, prolonged, and seamless protection against pathogens. In addition to E1/E3-defective adenovirus, other bioengineered non-replicating vectors encoding pathogen-derived antigens may also be developed into a new generation of rapid and prolonged immunologic-therapeutic (RAPIT).
    Type: Application
    Filed: December 30, 2013
    Publication date: May 22, 2014
    Applicant: VAXIN INC.
    Inventor: De-Chu C. Tang